Balyasny Asset Management
ALT icon

Balyasny Asset Management’s Altimmune ALT Stock Holding History

Balyasny Asset Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,000
Closed -$387K – 2872
2025
Q2 		$387K Buy
+100,000
New +$541K ﹤0.01% 2392
2015
Q4 		– Sell
-2,088
Closed -$833K – 1215
2015
Q3 		$833K Buy
+2,088
New +$989K 0.01% 745
2014
Q1 		– Sell
-38,095
Closed -$21.3M – 555
2013
Q4 		$21.3M Buy
38,095
+37,678
+9,035% +$22.5M 0.28% 97
2013
Q3 		$5.47M Buy
+417
New +$239K 0.07% 329

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Balyasny Asset Management's ALT Position: Q1 2026 in Review

Balyasny Asset Management sold out of Altimmune (ALT) in Q1 2026, closing a stake of 60,109 shares — an estimated $217K sold.

Balyasny Asset Management first reported a position in ALT in Q2 2022 and held it in 10 quarters. The position peaked at $13.3M in Q3 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Balyasny Asset Management reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 60,109 Altimmune shares in Q1 2026, an estimated $217K.
  • Balyasny Asset Management first reported a position in Altimmune in Q2 2022 and held it in 10 quarters.
  • Balyasny Asset Management's Altimmune position peaked at $13.3M in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.